Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Our "Peanut Allergy" Biotech Soared 50% in Yesterday's Debut

At its "coming-out party" yesterday, biotech Aimmune Therapeutics Inc. (Nasdaq: AIMT) proved to be every bit the hot initial public offering (IPO) that we've been expecting.

The Brisbane, Calif.-based biotech - which has developed one of the first true treatments for food-allergy sufferers - raised $160 million by selling 10 million shares of its stock to investors at $16 a share.

And once the shares made their debut, they skyrocketed from there.

Aimmune's shares soared as high as $27 each - a peak gain of 68.8%. Even after they backed off a bit, the stock was still trading at $23.86 - a hefty 50% gain.

Demand for the stock was stronger than expected...

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK